Insider trade

Beta Bionics (BBNX): CFO sold ~$17K

Stephen Feider, CFO at Beta Bionics, sold ~$17K of Beta Bionics shares.

~$17K
Approx. value · 951 sh @ $18.15
46K
Holds after · shares reported
Traded
Jun 2, 2025
Filed
Jun 4, 2025

What stands out in this filing

  • The sale was 2.0% of the shares this insider held before it; the filing reports 45,639 shares afterwards.
  • 951 shares at an average of $18.15 each, as reported on the form.
  • Footnote references tax withholding.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 2, 2025 · this disclosureInsiderCFO sold ~$17K of BBNX shares in the open market

What came next

  1. Jun 2, 2025Insider · 5 peopleInsiders: 14 sales (~$125K)
  2. Aug 19, 2025Insider · 2 peopleInsiders: 2 sales (~$364K)
  3. Aug 22, 2025InsiderCFO sold ~$75K of BBNX shares in the open market
  4. Sep 2, 2025Insider · 5 peopleInsiders: 5 sales (~$147K)
  5. Sep 4, 2025InsiderOfficer sold ~$136K of BBNX shares in the open market
  6. Sep 5, 2025Insider · 2 peopleInsiders: 2 sales (~$237K)
  7. Sep 8, 2025InsiderCFO sold ~$209K of BBNX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Beta Bionics

For Beta Bionics, OQRO holds 13 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BBNX page.

Other recent filings by Stephen Feider, Chief Financial Officer

The full history of Stephen Feider, Chief Financial Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Beta Bionics (BBNX) insider traded, and how much?

Stephen Feider, CFO at Beta Bionics, sold ~$17K of Beta Bionics shares. 951 shares at $18.15.

When did it happen, and when was it made public?

Traded: Jun 2, 2025. Filed: Jun 4, 2025. That is 2 days between the two dates.

What stands out in this filing?

The sale was 2.0% of the shares this insider held before it; the filing reports 45,639 shares afterwards. 951 shares at an average of $18.15 each, as reported on the form. Footnote references tax withholding.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Beta Bionics recently?

For Beta Bionics, OQRO holds 13 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the BBNX page.

Does this mean BBNX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Beta Bionics

Everything OQRO holds on this company is on its BBNX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data